Sarcopenia Pipeline Assessment (2023 Updates) | in-Depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA and EMA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 12+ key pharma and biotech companies are working on 14+ pipeline drugs in the Sarcopenia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Sarcopenia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Sarcopenia Market

The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Sarcopenia Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for the treatment of Sarcopenia and the aggregate therapies developed by major pharma companies.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sarcopenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 











Molecule Type

Products have been categorized under various Molecule types, such as



Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Sarcopenia Therapeutic Segment @

Sarcopenia Therapeutics Landscape

There are approx. 12+ key companies developing therapies for Sarcopenia. Currently, Biophytis is leading the therapeutics market with its Sarcopenia drug candidates in the most advanced stage of clinical development.

Latest Key Update in the Sarcopenia Therapeutics Market

On April 12, 2023, MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced a dosing update on its fully-funded Phase 2 clinical trial of lead drug candidate MYMD-1®, an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and frailty (NCT05283486).

The Leading Players in the Sarcopenia Therapeutics Market Include:

Actimed Therapeutics


Dystrogen Therapeutics

Eli Lily

Faraday Pharmaceuticals


Lipocine Inc.

MyMD Pharmaceuticals

NMD Pharma


Oncocross Therapeutics

OPKO health

Pephexia Therapeutics

Regeneron Pharmaceuticals

Rejuvenate Biomed

Rubedo Life Sciences


And Many Others

Sarcopenia Emerging and Marketed Drugs Covered in the Report Include:

Sarconeos (BIO101): Biophytis

MYMD-1: MyMD Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Sarcopenia Current Treatment Patterns

4. Sarcopenia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Sarcopenia Late Stage Products (Phase-III)

7. Sarcopenia Mid-Stage Products (Phase-II)

8. Sarcopenia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sarcopenia Discontinued Products

13. Sarcopenia Product Profiles

14. Key Companies in the Sarcopenia Market

15. Key Products in the Sarcopenia Therapeutics Segment

16. Dormant and Discontinued Products

17. Sarcopenia Unmet Needs

18. Sarcopenia Future Perspectives

19. Sarcopenia Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: